Pancreatic Paraganglioma in MEN Syndrome
Context Paragangliomas are rare neuroendocrine neoplasms arising from paraganglia of sympathetic trunk. Pancreatic localization is extremely rare (only 15 cases reported worldwide). Pancreatic paraganglioma has never been described before in the context of multiple endocrine neoplasia-1 (MEN 1) syndrome. Case report A 40-year-old male, known for previous follicular adenoma and primitive hyperparathyroidism, was admitted to our hospital with high blood pressure, flushing of the face, sweating and dysaesthesia of the lower limbs. Abdominal imaging showed multifocal pancreatic masses. He underwent total pancreatectomy with histological diagnosis of multifocal paraganglioma with a proliferative index (Ki67) of 10%. Further clinical evaluation evidenced pituitary microprolactinoma and adrenal hyperplasia. Even in the absence of genetic mutation, a diagnosis of MEN 1 syndrome was clinically established. During follow-up he developed liver metastatic disease that was treated with targeted biological therapy and multiple lines of chemotherapy. Conclusion A clinical presentation of MEN syndrome in absence of definable gene mutation is possible and becoming a clinical challenge. We discuss here a pancreatic paraganglioma presenting with rapid growth and prone to metastasis dissemination in a clinically evident MEN 1 syndrome. Further studies are needed to understand genetic causes and biology of this rare type of neuroendocrine tumor.
Copyright (c) 2014 Maria Cecilia Mariani, Claudio Cusini, Anna Dolcetta-Capuzzo, Valentina Villa, Giulia M Franchi, Gianpaolo Balzano, Marco F Manzoni
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.